Data to four years, in a phase II trial with the product in oral research of Genzyme Gauchers disease, suggests a significant improvement in all indicators.
Data to four years, in a phase II trial with the product in oral research of Genzyme Gaucher’s disease, suggests a significant improvement in all indicators. has already completed the recruitment in phase III of eliglustat...
Read More